Literature DB >> 14653622

Long-term cell survival and hemodynamic improvements after neonatal cardiomyocyte and satellite cell transplantation into healed myocardial cryoinfarcted lesions in rats.

Hanno Huwer1, Johannes Winning, Brigitte Vollmar, Cornelius Welter, Christoph Löhbach, Michael D Menger, Hans-Joachim Schäfers.   

Abstract

Cell engraftment is a new strategy for the repair of ischemic myocardial lesions. The hemodynamic effectiveness of this strategy, however, is not completely elucidated yet. In a rat model of cryothermia-induced myocardial dysfunction, we investigated whether syngeneic transplantation of neonatal cardiomyocytes or satellite cells is able to improve left ventricular performance. Myocardial infarction was induced in female Lewis rats by a standardized cryolesion to the obtuse margin of the left ventricle. After 4 weeks, 5 x 10(6) genetically male neonatal cardiomyocytes (n = 16) or satellite cells (n = 16) were engrafted into the myocardial scar. Sham-transplanted animals (n = 15) received injections with cell-free medium. Sham-operated animals (n = 15) served as controls. Left ventricular performance was analyzed 4 months after cell engraftment. Chimerism after this sex-mismatched transplantation was evaluated by detection of PCR-amplified DNA of the Y chromosome. The average heart weight of the infarcted animals significantly exceeded that of controls (p < 0.05). In sham-transplanted animals, mean aortic pressure, left ventricular systolic pressure, aortic flow (indicator of cardiac output), and left ventricular systolic reserve were significantly lower (p < 0.05) compared with sham-operated controls. This was associated with deterioration of ventricular diastolic function (maximal negative dP/dt, time constants of isovolumic relaxation; p < 0.05). Transplantation of satellite cells was found more effective than transplantation of neonatal cardiomyocytes, resulting in i) normalization of mean aortic pressure compared with sham-operated controls, and ii) significantly improved left ventricular systolic pressure and aortic flow (p < 0.05) compared with sham-transplanted animals. Left ventricular systolic reserve and diastolic function, however, were improved by neither satellite cell nor neonatal cardiomyocyte transplantation. Analysis of male genomic DNA revealed 3.98 +/- 2.70 ng in hearts after neonatal cardiomyocyte engraftment and 6.16 +/- 4.05 ng in hearts after satellite cell engraftment, representing approximately 10(3) viable engrafted cells per heart. Our study demonstrates i) long-term survival of both neonatal cardiomyocytes and satellite cells after transplantation into cryoinfarcted rat hearts, ii) slight superiority of satellite cells over neonatal cardiomyocytes in improving global left ventricular pump performance, and iii) no effect of both transplant procedures on diastolic dysfunction.

Entities:  

Mesh:

Year:  2003        PMID: 14653622     DOI: 10.3727/000000003108747361

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  10 in total

1.  The real estate of myoblast cardiac transplantation: negative remodeling is associated with location.

Authors:  Jonathan D McCue; Cory Swingen; Tanya Feldberg; Gabe Caron; Adam Kolb; Christopher Denucci; Somnath Prabhu; Randy Motilall; Brian Breviu; Doris A Taylor
Journal:  J Heart Lung Transplant       Date:  2008-01       Impact factor: 10.247

2.  Allogenic Myocytes and Mesenchymal Stem Cells Partially Improve Fatty Rotator Cuff Degeneration in a Rat Model.

Authors:  Mehmet F Güleçyüz; Konstanze Macha; Matthias F Pietschmann; Andreas Ficklscherer; Birte Sievers; Björn P Roßbach; Volkmar Jansson; Peter E Müller
Journal:  Stem Cell Rev Rep       Date:  2018-12       Impact factor: 5.739

Review 3.  The Heart and Great Vessels.

Authors:  Ekene Onwuka; Nakesha King; Eric Heuer; Christopher Breuer
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

4.  Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats.

Authors:  S Fernandes; A V Naumova; W Z Zhu; M A Laflamme; J Gold; C E Murry
Journal:  J Mol Cell Cardiol       Date:  2010-09-18       Impact factor: 5.000

5.  Bisphosphonate of Zoledronate Has Antiapoptotic Effect on Hypoxia/Reoxygenation Injury in Human Embryonic Stem Cell-Derived Cardiomyocytes Through Trk Signaling Pathway.

Authors:  Hua Wang; Wen-Shu Zhao; Lin Xu
Journal:  Cell Biochem Biophys       Date:  2022-02-28       Impact factor: 2.989

6.  MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases.

Authors:  Husnain Kh Haider; Ye Lei; Muhammad Ashraf
Journal:  Curr Opin Mol Ther       Date:  2008-12

7.  Label-free enrichment of functional cardiomyocytes using microfluidic deterministic lateral flow displacement.

Authors:  Boyang Zhang; James V Green; Shashi K Murthy; Milica Radisic
Journal:  PLoS One       Date:  2012-05-29       Impact factor: 3.240

8.  Cell therapy enhances function of remote non-infarcted myocardium.

Authors:  Alicia Moreno-Gonzalez; F Steven Korte; Jin Dai; Kent Chen; Bryan Ho; Hans Reinecke; Charles E Murry; Michael Regnier
Journal:  J Mol Cell Cardiol       Date:  2009-08-14       Impact factor: 5.000

Review 9.  Cell-Based Therapies for Cardiac Regeneration: A Comprehensive Review of Past and Ongoing Strategies.

Authors:  Andrea Ghiroldi; Marco Piccoli; Federica Cirillo; Michelle M Monasky; Giuseppe Ciconte; Carlo Pappone; Luigi Anastasia
Journal:  Int J Mol Sci       Date:  2018-10-16       Impact factor: 5.923

10.  Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts.

Authors:  Erik R Feest; F Steven Korte; An-Yue Tu; Jin Dai; Maria V Razumova; Charles E Murry; Michael Regnier
Journal:  J Mol Cell Cardiol       Date:  2014-03-29       Impact factor: 5.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.